Seeking Alpha

Gregory Block

Gregory Block
Send Message
View as an RSS Feed
View Gregory Block's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead's Harvoni cleared in Japan [View news story]
    DoctoRx, I echo your sentiments. '632's calls have tracked very well against the actual share price movement. Thanks for the fine-tuned analysis, '632!
    Jul 6, 2015. 11:20 AM | 1 Like Like |Link to Comment
  • Reports: Apple working on iPhone design that eliminates home button [View news story]
    Do you really think that EVERY change Apple makes has to be unique? if they only made changes that no other phone manufacturer has made, they'd be making phones that were scratch & sniff. And what's the utility of that?
    Jun 22, 2015. 04:14 PM | 4 Likes Like |Link to Comment
  • China rejects Gilead's hepatitis C patent [View news story]
    Welcome back, John!!
    Jun 19, 2015. 09:37 PM | Likes Like |Link to Comment
  • The Future Of Apple Hinges On The Mac Upsell [View article]
    @jon, I hope your liberal arts education teaches you the fallacy of argumentum ad hominem. I am pretty sure it's still taught in community colleges...
    Jun 19, 2015. 01:21 PM | 10 Likes Like |Link to Comment
  • Apple: What Is The Future Of The Mac? [View article]
    @JDEvolutionist, I envy you. I was stuck with a HP 125...
    Jun 19, 2015. 01:08 PM | 2 Likes Like |Link to Comment
  • The Future Of Apple Hinges On The Mac Upsell [View article]
    jon coyne, please explain your "u went to community college" remark. Disparaging remarks have no place in an investment forum.
    Jun 19, 2015. 11:41 AM | 10 Likes Like |Link to Comment
  • China rejects Gilead's hepatitis C patent [View news story]
    Agreed, JK. All the author has to do is change:

    "Sovaldi costs $1,000 per pill in the U.S., or $84,000 for a typical 12-week course."

    to:

    "The list price of Sovaldi (not including discounts) is $1,000 per pill in the U.S., or $84,000 for a typical 12-week course."

    It seems that the author tweaked the verbiage slightly from the original Reuters article:

    "Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which costs $1,000 per pill in the United States. That adds up to $84,000 for a typical 12-week course."

    Again, it's just a copy & paste with no investigative rigor.
    Jun 19, 2015. 08:45 AM | 8 Likes Like |Link to Comment
  • China rejects Gilead's hepatitis C patent [View news story]
    Seeking Alpha is rapidly becoming a source of misinformation. Its authors and contributors copy & paste misinformation from other sources, and then are quoted in downstream articles. Seeking Alpha has crowdsourced analysis, and evidently fact-checking as well.
    Jun 19, 2015. 07:20 AM | 26 Likes Like |Link to Comment
  • China rejects Gilead's hepatitis C patent [View news story]
    HL, you are making 133's point. Since Sovaldi is the brand name of sofosbuvir, it cannot be the "main ingredient" as the article states.
    Jun 19, 2015. 07:17 AM | 6 Likes Like |Link to Comment
  • Treat Yourself To A Modest Amount Of The Mindbody IPO [View article]
    I have a personal interest in watching the results of the IPO. Thanks for the write-up!
    Jun 17, 2015. 09:56 AM | 1 Like Like |Link to Comment
  • Biotech Bio-Hazard [View article]
    "Since my article is on IBB and not GILD, I didn't double check whether that was accurate..."

    Sorry, your article is on GILD, since you devoted a few paragraphs to citing your shallow research on Gilead, including its pricing. Your facts have to be correct if you want to support your theme. Since you got your facts wrong, how does that lend credibility to your theme?

    Respectfully, your best option is to publish a retraction, not blithely defend your mistake.
    Jun 17, 2015. 07:17 AM | 5 Likes Like |Link to Comment
  • Biotech Bio-Hazard [View article]
    D. Rockefeller, I am surprised you neglected to mention the grassy knoll.
    Jun 17, 2015. 07:11 AM | 2 Likes Like |Link to Comment
  • Biotech Bio-Hazard [View article]
    I was wondering why the author quoted the $84,000 list price when it has been well-documented on SA that Sovaldi pricing is not at list. Mistakes like this indicate shallow, ill-informed research which diminishes the author's credibility.
    Jun 16, 2015. 07:22 PM | 6 Likes Like |Link to Comment
  • NASH - The Silent Killer You've Never Heard Of... But You Will [View article]
    @Logribel, why do you write, "supposedly MD"? If you have proof the author is not an MD, please share it. Otherwise, why impugn him?
    Jun 13, 2015. 09:55 PM | 3 Likes Like |Link to Comment
  • NASH - The Silent Killer You've Never Heard Of... But You Will [View article]
    What's with the "so-called MD" reference? If you have proof the author is not an MD, let's hear it.
    Jun 13, 2015. 09:47 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
302 Comments
620 Likes